16A: Performance, acceptability, and validation of a phone application bowel diary - 28/02/20
Plan
| DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS: Halina Zyczynski: Nothing to disclose; Holly E. Richter: Allergan, investigator, research contract; Renovia, investigator, research contract; BlueWind Medical, DSMB member, consulting fee; Emily Lukacz: Axonics, consultant, consulting fee; Boston Scientific, investigator, research grant; Uroplasty/Cogentix, investigator, research grant; UpToDate, author, royalties; Vivian Sung: Nothing to disclose; Lily A. Arya: Nothing to disclose; David D. Rahn: Nothing to disclose; Anthony G. Visco: Nothing to disclose; Benjamin Carper: Nothing to disclose; Donna Mazloomdoost: Boston Scientific, Project Scientist PFDN, Grant to the PFDN for SUPeR Trial; Marie G. Gantz: Medspira, PI Data Coordinating Center, Discounted equipment in exchange for PFDN consultation on biofeedback software. |
Vol 222 - N° 3S
P. S784-S785 - mars 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
